文献库搜索 | GeneLibs

Chen(HR),Huang(ZY),Ren(ZR),Lu(C),Ding(YZ),... Zhonghua Bing Li Xue Za Zhi 2026-05-08

...PIK3CA mutations, but PIK3CA mutation is not the main mechanism of targeted therapy resistance in lung adenocarcinoma pa...

Marchiò(C),Rojo(F),Copson(ER),Schmitt(F),B... NPJ Breast Cancer 2026-05-15

PIK3CA mutations are common in HR+/HER2- metastatic breast cancer and guide the use of PI3K-targeted therapies. This exp...

Brown(MH),Mendes(WS),Song(Y),Shetty(AC),Wi... Oral Oncol 2026-08-00

...PIK3CA, RB1, FBXW7, FGFR3, TP53, CYLD, B2M, FLCN, FGF23, and ERBB2. Compared to reported rates in predominantly advanced...

Leone Roberti Maggiore(U),Vignali(M),Kvask... Hum Reprod Update 2026-05-17

...PIK3CA, and KRAS are shared between endometriosis and certain OC subtypes, and the nature of the environment typical of ...

Jani(CT),Tran(E),Zhang(N),Tsai(J),Dong(J),... Clin Cancer Res 2026-05-15

...PIK3CA (9.4%/15.9%), and EGFR (9.6%/14.6%). All treatment cohorts showed a significant increase in mutation burden after...

Suzuki(S),Seino(M),Sato(H),Kawai(M),Ogura(... Pharmaceuticals (Basel) 2026-02-12

...PIK3CA (46.0%) were the most prevalent genomic alterations in the MpBC cohort. Exploratory analysis suggested that PIK3C...

Rossi(S),Pagliaro(A),Masini(S),Finocchiaro... Biomedicines 2026-02-04

...PIK3CA mutation subtypes or treatment strategies. Conclusions: PIK3CA-altered NSCLC represents a molecularly heterogeneo...

Desai(C),Wang(P),Tjota(M),Lastra(RR) Int J Gynecol Pathol 2026-02-02

...PIK3CA, APC, and NF1. The aforementioned findings mirror those found in metaplastic carcinoma of the breast, and a diagn...

Che(J),Kwon(WS),Kim(J),Jadamba(E),Han(HJ),... Sci Rep 2026-02-10

...PIK3CA, and CNVs, e.g., ERBB2 amplification in gastric (n = 412) and colorectal (n = 66) cancers. MSI and TMB were stron...

Liu(L),Graff(SL),Hacking(S),Cheng(L),Wang(... Histopathology 2026-06-00

...PIK3CA and TP53 mutations and treatment-emergent ESR1 mutations, observed in both tissue and ctDNA. CDKN2A, SPEN, KIT, C...